The Global Inhalation Capsules Market size is expected to reach $1.4 billion by 2031, rising at a market growth of 5.9% CAGR during the forecast period.
Several factors contribute to the high prevalence of asthma in the U.S., including air pollution, allergens, tobacco smoke, and obesity. Urban areas, particularly in the Northeast and Midwest, have higher asthma rates due to higher air pollution and allergens. Consequently, the North America region generated USD 312.7 million revenue of the market in 2023. Moreover, the region has high healthcare spending, allowing patients better access to advanced treatment options, including inhalation capsules.
Technological advancements have resulted in the development of inhalation devices that are easier to use and more intuitive for patients. Features such as one-click mechanisms, ergonomic designs, and simplified instructions make inhalation devices more user-friendly, improving patient adherence and satisfaction. Advanced inhalation devices incorporate mechanisms to ensure precise and consistent medication dosing. Therefore, as these technological advancements evolve, the market is expected to expand further.
Additionally, as healthcare infrastructure improves and access to medical services increases, a growing demand for effective and convenient treatment options for respiratory diseases drives the demand for inhalation capsules. For example, in countries like China and India, where the healthcare industry is rapidly expanding, there is a significant increase in the prevalence of respiratory diseases due to factors such as air pollution and smoking. Hence, the substantial expansion of the healthcare industry globally has created a conducive environment for the growth of the market.
However, Inhalation capsules deliver medication directly to the lungs, but some amount of the drug may enter the bloodstream and cause systemic side effects. These side effects can include cardiovascular effects, changes in blood pressure, or alterations in metabolic parameters. Particularly with prolonged use or high doses, patients and medical professionals may be concerned about the potential for systemic adverse effects associated with inhalation therapies. Hence, these factors may hamper the market's growth.
Furthermore, the COVID-19 pandemic reshaping demand dynamics, supply chains, and healthcare delivery methods. With the heightened focus on respiratory health during the pandemic, there was an increased demand for medications delivered via inhalation capsules, driven by patients seeking to manage respiratory conditions such as asthma and COPD. Thus, the pandemic had an overall positive impact on the market.
Several factors contribute to the high prevalence of asthma in the U.S., including air pollution, allergens, tobacco smoke, and obesity. Urban areas, particularly in the Northeast and Midwest, have higher asthma rates due to higher air pollution and allergens. Consequently, the North America region generated USD 312.7 million revenue of the market in 2023. Moreover, the region has high healthcare spending, allowing patients better access to advanced treatment options, including inhalation capsules.
Technological advancements have resulted in the development of inhalation devices that are easier to use and more intuitive for patients. Features such as one-click mechanisms, ergonomic designs, and simplified instructions make inhalation devices more user-friendly, improving patient adherence and satisfaction. Advanced inhalation devices incorporate mechanisms to ensure precise and consistent medication dosing. Therefore, as these technological advancements evolve, the market is expected to expand further.
Additionally, as healthcare infrastructure improves and access to medical services increases, a growing demand for effective and convenient treatment options for respiratory diseases drives the demand for inhalation capsules. For example, in countries like China and India, where the healthcare industry is rapidly expanding, there is a significant increase in the prevalence of respiratory diseases due to factors such as air pollution and smoking. Hence, the substantial expansion of the healthcare industry globally has created a conducive environment for the growth of the market.
However, Inhalation capsules deliver medication directly to the lungs, but some amount of the drug may enter the bloodstream and cause systemic side effects. These side effects can include cardiovascular effects, changes in blood pressure, or alterations in metabolic parameters. Particularly with prolonged use or high doses, patients and medical professionals may be concerned about the potential for systemic adverse effects associated with inhalation therapies. Hence, these factors may hamper the market's growth.
Furthermore, the COVID-19 pandemic reshaping demand dynamics, supply chains, and healthcare delivery methods. With the heightened focus on respiratory health during the pandemic, there was an increased demand for medications delivered via inhalation capsules, driven by patients seeking to manage respiratory conditions such as asthma and COPD. Thus, the pandemic had an overall positive impact on the market.
By Application Analysis
On the basis of application, the market is classified into asthma treatment, COPD management, and others. The asthma treatment segment procured 48.5% revenue share in the market in 2023. Asthma treatment within the market encompasses a wide range of medications and delivery devices tailored to manage the symptoms and underlying inflammation associated with this chronic respiratory condition. Inhalation therapy is considered the cornerstone of asthma management because it delivers medications directly to the lungs, resulting in rapid onset of action, targeted treatment, and reduced systemic side effects.
By Type Analysis
Based on type, the market is characterized by gelatin capsules and hypromellose capsules. In 2023, the hypromellose capsules segment recorded a 38.2% revenue share in the market. Hypromellose capsules, also known as hydroxypropyl methylcellulose (HPMC) capsules, are gaining within the market. HPMC capsules offer several key benefits that make them well-suited for inhalation therapy. This versatility enables pharmaceutical companies to develop inhalation capsules containing various active pharmaceutical ingredients, catering to the specific needs of patients with different respiratory conditions.By Regional Analysis
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Europe region held a 29.3% revenue share in the market in 2023. Europe is a leader in healthcare technology, leading to the development of advanced inhalation devices and formulations that drive market growth. Patients and healthcare professionals alike are well-informed regarding the advantages of inhalation therapy, which is propelling market expansion. Moreover, Europe has a favorable regulatory environment for developing and commercializing inhalation capsules, encouraging market growth.Recent Strategies Deployed in the Market
- Mar-2024: AstraZeneca Pharma India Limited, a subsidiary of AstraZeneca PLC, signed an agreement with Mankind Pharma Limited, a pharmaceutical company. Under this agreement, Mankind Pharma will exclusively distribute budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India.
- Dec-2023: AstraZeneca PLC got approval for its inhalation aerosol from the Central Drugs Standard Control Organisation (CDSCO). The inhalation aerosol consists of a triple combination of budesonide (160 mcg), glycopyrrolate (9 mcg), and formoterol fumarate (4.8 mcg) and is prescribed for the treatment and maintenance of patients with chronic obstructive pulmonary disease (COPD).
- May-2021: Vectura Group Plc expanded its dry powder inhaler (DPI) development and manufacturing capabilities at its facility in Chippenham, U.K. Through this expansion, the company aims to facilitate integration with capsule inhaler devices, such as Vectura’s open inhale close (OIC) device and the lever-operated multi-dose inhaler (LOMI) device utilized in Hikma’s generic Advair product.
- Mar-2021: Chiesi USA, Inc., a subsidiary of Chiesi Farmaceutici S.p.A., unveiled its bronchitol (mannitol) inhalation powder. The product is a dry powder-inhaled mucoactive agent that is compact, discrete, and portable and does not necessitate any nebulization, refrigeration, or routine cleaning.
- Nov-2020: Chiesi Farmaceutici S.p.A. came into a partnership with Kaia Health Software GmbH, a digital therapeutics company. Under this partnership, the companies will market the Kaia Health Chronic Obstructive Pulmonary Disease (COPD) Pulmonary Rehabilitation app across Europe. Additionally, the partnership aims to provide patients with a digital therapeutic tool that facilitates COPD treatment outcomes by fostering behaviour change.
List of Key Companies Profiled
- Cipla Limited
- Novartis AG
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Lonza Group Ltd. (Capsugel)
- Chiesi Farmaceutici S.p.A
- Vectura Group Plc (Philip Morris International, Inc.)
- Elpen S.A.
- Healthcaps India Ltd.
- Qualicaps Co., LTD. (Roquette Freres SA)
Market Report Segmentation
By Type- Gelatin Capsules
- Hypromellose Capsules
- Asthma Treatment
- COPD Management
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Global Inhalation Capsules Market by Type
Chapter 6. Global Inhalation Capsules Market by Application
Chapter 7. Global Inhalation Capsules Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- Cipla Limited
- Novartis AG
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Lonza Group Ltd. (Capsugel)
- Chiesi Farmaceutici S.p.A
- Vectura Group Plc (Philip Morris International, Inc.)
- Elpen S.A.
- Healthcaps India Ltd.
- Qualicaps Co., LTD. (Roquette Freres SA)
Methodology
LOADING...
